BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

708 related articles for article (PubMed ID: 7593445)

  • 1. Nocturnal augmentation of growth hormone (GH) secretion is preserved during repetitive bolus administration of GH-releasing hormone: potential involvement of endogenous somatostatin--a clinical research center study.
    Jaffe CA; Turgeon DK; Friberg RD; Watkins PB; Barkan AL
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3321-6. PubMed ID: 7593445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH-deficient boy.
    Vance ML; Kaiser DL; Martha PM; Furlanetto R; Rivier J; Vale W; Thorner MO
    J Clin Endocrinol Metab; 1989 Jan; 68(1):22-8. PubMed ID: 2491864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous 24-hour intravenous infusion of recombinant human growth hormone (GH)-releasing hormone-(1-44)-amide augments pulsatile, entropic, and daily rhythmic GH secretion in postmenopausal women equally in the estrogen-withdrawn and estrogen-supplemented states.
    Evans WS; Anderson SM; Hull LT; Azimi PP; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Feb; 86(2):700-12. PubMed ID: 11158034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired inhibitory effects of somatostatin on growth hormone (GH)-releasing hormone stimulation of GH secretion after short term infusion.
    Kelijman M; Frohman LA
    J Clin Endocrinol Metab; 1990 Jul; 71(1):157-63. PubMed ID: 1973420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of pulsatile administration, continuous infusion, and diurnal variation on the growth hormone (GH) response to GH-releasing hormone in normal men.
    Hulse JA; Rosenthal SM; Cuttler L; Kaplan SL; Grumbach MM
    J Clin Endocrinol Metab; 1986 Oct; 63(4):872-8. PubMed ID: 3091629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men.
    Jaffe CA; Ho PJ; Demott-Friberg R; Bowers CY; Barkan AL
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1641-7. PubMed ID: 7903313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of growth hormone secretion from porcine fetal and neonatal pituitary tissue in vitro by growth hormone-releasing hormone, somatostatin, and insulin-like growth factor.
    Torronteras R; Gracia-Navarro F; Elsaesser F
    Neuroendocrinology; 1997 Feb; 65(2):117-28. PubMed ID: 9067989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus.
    Huhn WC; Hartman ML; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1993 May; 76(5):1202-8. PubMed ID: 8496311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotrophic, IGF-I, and IGF-binding protein responses to a three-day intravenous growth hormone-releasing hormone pulsatile infusion in men.
    Iranmanesh A; South S; Liem AY; Clemmons D; Thorner MO; Weltman A; Veldhuis JD
    Eur J Endocrinol; 1998 Jul; 139(1):59-71. PubMed ID: 9703380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short term continuous intravenous infusion of growth hormone (GH) inhibits GH-releasing hormone-induced GH secretion: a time-dependent effect.
    Rosenthal SM; Kaplan SL; Grumbach MM
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1101-5. PubMed ID: 2498383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous subcutaneous infusions of growth hormone (GH) releasing hormone 1-44 for 14 days increase GH and insulin-like growth factor-I levels in old men.
    Corpas E; Harman SM; Piñeyro MA; Roberson R; Blackman MR
    J Clin Endocrinol Metab; 1993 Jan; 76(1):134-8. PubMed ID: 8421077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the somatotropic axis by testosterone in adult men: evidence for a role of hypothalamic growth hormone-releasing hormone.
    Bondanelli M; Ambrosio MR; Margutti A; Franceschetti P; Zatelli MC; degli Uberti EC
    Neuroendocrinology; 2003 Jun; 77(6):380-7. PubMed ID: 12845224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual effects of growth hormone (GH)-releasing hormone infusion in normal men: somatotroph desensitization and increase in releasable GH.
    Vance ML; Kaiser DL; Rivier J; Vale W; Thorner MO
    J Clin Endocrinol Metab; 1986 Mar; 62(3):591-4. PubMed ID: 3080467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A persistent pattern of varying pituitary responsivity to exogenous growth hormone (GH)-releasing hormone in GH-deficient children: evidence supporting periodic somatostatin secretion.
    Martha PM; Blizzard RM; McDonald JA; Thorner MO; Rogol AD
    J Clin Endocrinol Metab; 1988 Sep; 67(3):449-54. PubMed ID: 2900843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repetitive injections of growth hormone releasing hormone (GHRH1-44) to normal volunteers and patients with growth hormone deficiency.
    Hümmelink R; Sippell WG
    Horm Metab Res; 1990 Feb; 22(2):101-8. PubMed ID: 2182500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulsatile growth hormone secretion in patients with acromegaly and normal men: the effects of growth hormone-releasing hormone infusion.
    Gelato MC; Oldfield E; Loriaux DL; Merriam GR
    J Clin Endocrinol Metab; 1990 Sep; 71(3):585-90. PubMed ID: 2118536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.
    Bowers CY; Granda-Ayala R
    Endocrine; 2001 Feb; 14(1):79-86. PubMed ID: 11322505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
    Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Awouters M; Verbruggen W; Schetz M; Verwaest C; Lauwers P; Bouillon R; Bowers CY
    J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
    Ionescu M; Frohman LA
    J Clin Endocrinol Metab; 2006 Dec; 91(12):4792-7. PubMed ID: 17018654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of growth hormone-releasing hormone and somatostatin to decreased growth hormone secretion in elderly men.
    Soule SG; Macfarlane P; Levitt NS; Millar RP
    S Afr Med J; 2001 Mar; 91(3):254-60. PubMed ID: 11291426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.